Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsAssociation between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-AnalysisDose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatricsOptimizing the Clinical Use of VancomycinNovel pandemic influenza A (H1N1) and community-associated methicillin-resistant Staphylococcus aureus pneumonia.Comparison of open-access vancomycin dosing websites.Does contemporary vancomycin dosing achieve therapeutic targets in a heterogeneous clinical cohort of critically ill patients? Data from the multinational DALI study.Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal functionClinical outcomes of linezolid and vancomycin in patients with nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus stratified by baseline renal function: a retrospective, cohort analysis.Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infectionsPopulation pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.Predictors of Adverse Outcomes in Children With Staphylococcus aureus BacteremiaUse of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infectionsThe Whole Price of Vancomycin: Toxicities, Troughs, and TimeProspective validation of neonatal vancomycin dosing regimens is urgently needed.Vancomycin monitoring in children using bayesian estimation.Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.Questioning the accuracy of trough concentrations as surrogates for area under the curve in determining vancomycin safety.Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.Evaluation of a Once-Daily Vancomycin Regimen in an Outpatient Leukemia/Bone Marrow Transplant Clinic (OD-VANCO Study)Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections.Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysisVancomycin revisited - 60 years laterTherapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients.Association between vancomycin trough concentration and area under the concentration-time curve in neonatesPrediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulationCurrent recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate.Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens.Teicoplanin dosing strategy for treatment of Staphylococcus aureus in Korean patients with neutropenic feverCurrent and novel antibiotics against resistant Gram-positive bacteriaHigh versus low vancomycin serum trough regimen for Gram-positive infections: a meta-analysis.Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.How to treat VAP due to MDR pathogens in ICU patients.Penetration of vancomycin into epithelial lining fluid in healthy volunteers.Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.In vitro activities of daptomycin-, vancomycin-, and teicoplanin-loaded polymethylmethacrylate against methicillin-susceptible, methicillin-resistant, and vancomycin-intermediate strains of Staphylococcus aureus.Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis.
P2860
Q24646677-5165F03E-4426-4A78-9A2F-B790EE7E2346Q26770913-995D3DC5-9891-4D80-AFAB-471606969748Q26853629-68DEBBE4-0533-4956-8088-7000D3352416Q28069334-8D97DC60-1CDF-4BC3-9EB0-35CC57F7CD20Q30370676-85966C32-8E17-49F6-958B-9DA3C2250FF6Q30490223-5034A93A-65B5-4561-B074-616BF2BDEC14Q30828312-B30D5573-D1B7-42C2-B9C4-8331EC10E190Q33613764-7C89398F-36E7-4D7E-ADB1-A003B1FDC7BAQ33716771-08FA7457-5B5B-4915-981F-299A5A91FAD1Q33767602-33B71E2B-ABBC-400E-BA28-526A5F5F1C54Q33797950-337C9B3C-933A-4F7F-933C-CB75D06966ADQ33806504-BB94A0D3-15D0-44AB-A692-C417DA6BD312Q33881584-3A8F94EB-621E-4659-909B-C9001C87452FQ33885191-1C3575C5-F93A-460E-89D7-FBE5638F459BQ33906451-A255CF95-9D01-4D53-B2FA-AC692F375DA0Q33911485-730EF864-E14E-439C-9866-F49C7580841CQ33926436-1B1E0CEB-B4D9-4DC0-932D-E63C32B6C355Q33949459-D96D895D-2392-42F0-A7AE-D1D1917EAB39Q33997671-929BF109-4E83-4250-B5CE-3842E87C7752Q34026240-DE2B5460-BF31-4BCE-93A9-03F40947263AQ34125504-F1C0A417-5462-4C7A-9056-CE11D6AB93A9Q34157657-7AB9F5C6-8E0A-4218-9833-BEAC0C5B4A18Q34274190-0496C5AD-51B7-488B-9B96-CEBFCCDED88BQ34403094-A0119CFC-1C92-4BED-917D-A22877254B08Q34405301-0CED3823-2D65-43DA-B235-467C210D2563Q34433066-90843AB8-2F53-49F5-AC76-CD521A94F966Q34494676-BEA91EFD-D030-4050-AE23-4B54E23EB5A1Q34596435-487D10F5-EEFD-45D6-B831-5B82541A8A3FQ34989352-985EA189-1FCD-4B12-8BFF-6EC27CEC3138Q35004264-B3E44C4F-E663-4F54-A225-2F7425F6ED75Q35004943-3EB47AFA-1A2B-443C-A130-748449F38084Q35014842-F518DEDA-CF04-4AC0-BE0E-24BB42731A4CQ35026521-72FB4114-3EE5-4D66-94F3-CDC8EAA106B5Q35123536-FEEE031A-D7F5-4F2A-A716-FD637F858067Q35191519-2FB8BD11-A798-410D-867A-B5538E9D0BAEQ35457068-F61A0A54-BC1D-4157-9E36-E6A038F7FC1DQ35598408-C37F2DE1-771D-404C-B276-460842F4D828Q35598479-17C28540-1E20-4AE9-8334-0897EBA2C3C0Q35598497-45541494-572A-4D5C-89E5-B39B575B1CC1Q35607636-790A3AAF-12FD-4CC8-8900-63FA6ABBE852
P2860
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pharmacodynamics of vancomycin ...... respiratory tract infections.
@en
Pharmacodynamics of vancomycin ...... respiratory tract infections.
@nl
type
label
Pharmacodynamics of vancomycin ...... respiratory tract infections.
@en
Pharmacodynamics of vancomycin ...... respiratory tract infections.
@nl
prefLabel
Pharmacodynamics of vancomycin ...... respiratory tract infections.
@en
Pharmacodynamics of vancomycin ...... respiratory tract infections.
@nl
P2093
P1476
Pharmacodynamics of vancomycin ...... respiratory tract infections.
@en
P2093
Alan Forrest
Jerome J Schentag
Mary C Birmingham
Pamela A Moise-Broder
P304
P356
10.2165/00003088-200443130-00005
P577
2004-01-01T00:00:00Z
P6179
1015038530